Allogene Therapeutics (Nasdaq: ALLO) has terminated its five-year regional licensing agreement with Overland Therapeutics, reclaiming full global rights to four allogeneic CAR T cell programs targeting BCMA, CD70, FLT3, and DLL3, according to an 8-K filing submitted to the SEC on May 13, 2026. The termination, executed with no payments exchanged, unwinds a deal originally valued at USD 119 million in upfront consideration and closes out Overland's exclusive development and commercialization rights across Greater China, Taiwan, South Korea, and Singapore.
Under the original December 2020 agreement, Allogene received USD 40 million in cash and USD 79 million in Overland Series Seed preferred stock, plus up to USD 40 million in contingent regulatory milestones and a flat mid-single-digit royalty on net sales. None of the regulatory milestones appear to have been triggered prior to termination. As part of the restructuring, Allogene surrendered a portion of its Overland equity for no consideration and now holds approximately 3% of Overland's outstanding shares on an as-converted, fully diluted basis.
Deal context
The four programs covered by the agreement — ALLO-715, ALLO-316, ALLO-605, and ALLO-819 — are all derived from Allogene's AlloCAR T platform, which uses TALEN nuclease gene editing, licensed from Cellectis (Euronext Growth: ALCLS / Nasdaq: CLLS), to knock out the TRAC and CD52 genes in healthy donor T cells. TRAC disruption eliminates the endogenous T-cell receptor, preventing graft-versus-host disease when cells are infused into unrelated patients. CD52 knockout renders the engineered cells resistant to alemtuzumab, an antibody used in the lymphodepletion conditioning regimen, allowing the allogeneic product to survive and expand while the patient's own immune cells are depleted.
ALLO-715 and ALLO-605 both target BCMA and are intended for relapsed or refractory multiple myeloma, with ALLO-715 representing the first allogeneic BCMA CAR T to enter clinical trials and ALLO-605 a next-generation iteration with enhanced persistence features. ALLO-316 targets CD70, which is overexpressed in renal cell carcinoma and certain hematologic malignancies, and reached Phase I evaluation. ALLO-819 targets FLT3 and DLL3, relevant to acute myeloid leukemia and small cell lung cancer respectively.
Allogene's primary clinical focus has shifted toward cemacabtagene ansegedleucel (cema-cel), its CD19-directed allogeneic CAR T candidate. In April 2026, Allogene reported interim futility analysis data from the pivotal Phase II ALPHA3 trial showing 58.3% minimal residual disease clearance with cema-cel versus 16.7% in the observation arm in first-line consolidation large B-cell lymphoma. The company subsequently expanded the ALPHA3 trial to South Korea and Australia following regulatory clearance in both markets.
Industry and transaction context
The termination potentially reflects a broader pattern of US biotechs unwinding China-region licensing deals struck during the 2019–2021 window, when Greater China partnerships were a common mechanism for non-dilutive financing. Many of those agreements were structured with equity components in the Chinese licensee rather than pure cash, creating valuation exposure as the capital environment in China's biopharma sector contracted. The USD 79 million non-cash component of the original Allogene-Overland deal — received as preferred stock in a private entity — illustrates that structure, and Allogene's decision to surrender equity for no consideration on exit suggests the residual value of that stake was limited.